MedTrace Logo

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

NCT04367883 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-03-25

No results posted yet for this study

Summary

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Conditions

  • COVID19
  • Influenza Vaccination
  • ACE Inhibitors
  • ARB
  • Antihistamine Allergy
  • Amantadine

Interventions

DRUG

Antihistamine

No intervention is performed. We propose an observational study.

DRUG

Amantadine

No intervention is performed. We propose an observational study

DRUG

ACEI

No intervention is performed. We propose an observational study.

DRUG

ARB

No intervention is performed. We propose an observational study.

OTHER

Influenza vaccine and COVID

No intervention is performed. We propose an observational study.

Sponsors & Collaborators

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

    collaborator OTHER

  • Institut Català de la Salut

    collaborator OTHER

  • Consorci Sanitari de Terrassa

    lead OTHER

Principal Investigators

  • Anna Puigdellívol-Sánchez, Ph D · Consorci Sanitari de Terrassa

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2025-01-19
Completion
2028-02-24
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04367883 on ClinicalTrials.gov